@FiercePharma: Allergan got its bladder-control indication for Botox: FDA OKs wrinkle-fighter for incontinence in certain patients. News | Follow @FiercePharma
> Shire has discontinued development of its Dermagraft product, acquired along with Advanced BioHealing earlier this year, for treatment of venous leg ulcers after it failed a new trial; the indication had been expected to add $160 million to sales. News
> The FDA warned that using high doses of the Forest Laboratories ($FRX) antidepressant Celexa could increase the risk of heart-rhythm problems. Item
> The U.K.'s cost-effectiveness watchdog gave its final "no" to Bristol-Myers Squibb's ($BMY) drug Orencia as a second-line treatment for rheumatoid arthritis patients who've failed on non-biologic treatments. Story
> India's Cipla expects 14% growth this year as it invests $130.4 million into active pharmaceutical ingredients facilities around its home market. Article
> Baxter International ($BAX) agreed to pay $380 million for Baxa, which develops pharmacy technology for oral and IV dose preparation and delivery, in a deal designed to enhance Baxter's nutrition and drug-delivery business. Baxter release
> Afexa Life Sciences says it's casting about for white-knight bidders to beat a $57.3 million buyout offer from Paladin Labs. Report
> Sunovion Pharmaceuticals chose Mark Iwicki as its new CEO, replacing Saburo Hamanaka, who took the slot after the company was purchased by Japanese drugmaker Dainippon Sumitomo. News
> Elan shares rose after an analyst upped her forecast for sales for the multiple sclerosis drug Tysabri. Item
> Chinese drug distributor Sinopharm saw first-half profits grow by 23% to $123 million after two acquisitions. Story
> Drug delivery and coating specialists SurModics is planning to cut 9% of its staff in a restructuring that could also include the sale of its pharma-oriented unit, so it can focus on diagnostics alone. Piece
> Prescriptions for diabetes meds cost the U.K.'s National Health Service £725 million, or 8.4% of the system's primary care drug spending. More
> Hikma Pharmaceuticals saw revenue grow to $395.7 million for its most recent quarter, but profit fell by about a third to $49 million. Story
> Dey Pharma, a subsidiary of Mylan ($MYL), is offering new versions of its EpiPen products: the EpiPen 2-Pak and EpiPen Jr 2-Pak. Item
> InVentiv is launching a new company, InVentiv Health Communications/Europe, that will house all its healthcare communications services under one roof. Report
Biotech News
@FierceBiotech: Boehringer Ingelheim gets the dirt flying on $42.5M R&D facility. Item | Follow @FierceBiotech
@JohnCFierce: Top execs at Novo Nordisk are getting a brand spanking new HQ building in Bagsvaerd. Story | Follow @JohnCFierce
@RyanMFierce: OpenClinica (open source EDC provider) strikes pact to bring software to evolving clinical trials market in China. Release | Follow @RyanMFierce
@MaureenFierce: IOM: Vaccines cause very few side effects. Report | Follow @MaureenFierce
> Oxygen Biotherapeutics CEO Stern gets the heave-ho. Details
> Top scientists at U.K. cancer drug upstart raise $10M A round. Story
> Is GSK finally ready to move on Human Genome Sciences bid? Report
> Lilly, Boehringer collaboration score a win with European linagliptin approval. Item
> Shire battles back to win FDA OK for HAE drug Firazyr. News
Manufacturing News
> FDA eyes TN wholesalers for black market ops. More
> Teva propofol plant closing following jury award for hep C outbreak. News
> Pfizer, Qiagen seize companion diagnostics play. Article
> U.K. competition heats up for new GSK plant. Story
> China's drug regulator reins in CMOs. Details
> Disposables maker PBS takes run at Pall, Sartorius. Report
Vaccine News
> Researchers hope to boost body's response to chronic infections. News
> Two Rift Valley fever vaccines provide solid results. Article
> Study explains how FluMist works. More
> When it comes to vaccinnes, 'tweens' often overlooked. Details
> GSK's Ceravix prevents anal cancer in women. Report
And Finally... Exercise can be as effective as an add-on "medication" for depression patients who don't respond fully to a single drug. Article